MX2021012548A - Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel. - Google Patents
Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel.Info
- Publication number
- MX2021012548A MX2021012548A MX2021012548A MX2021012548A MX2021012548A MX 2021012548 A MX2021012548 A MX 2021012548A MX 2021012548 A MX2021012548 A MX 2021012548A MX 2021012548 A MX2021012548 A MX 2021012548A MX 2021012548 A MX2021012548 A MX 2021012548A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- skin diseases
- topical compositions
- inflammatory skin
- treating inflammatory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen composiciones y métodos para tratar afecciones, dolencias o enfermedades de la piel, tales como enfermedades cutáneas autoinflamatorias como psoriasis, dermatitis, pioderma gangrenoso, pustulosis palmoplantar, prurigo nodular y/o hidradenitis supurativa. Las composiciones comprenden un agente que modula el receptor de hidrocarburos de arilos, en particular un agente que agoniza el receptor. En una modalidad, el agente es el índigo o un derivado del índigo, tal como la indirrubina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962835451P | 2019-04-17 | 2019-04-17 | |
US201962924611P | 2019-10-22 | 2019-10-22 | |
PCT/US2020/028581 WO2020214855A1 (en) | 2019-04-17 | 2020-04-16 | Topical compositions and methods for treating inflammatory skin diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021012548A true MX2021012548A (es) | 2023-01-05 |
Family
ID=70614619
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021012548A MX2021012548A (es) | 2019-04-17 | 2020-04-16 | Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel. |
MX2023000291A MX2023000291A (es) | 2019-04-17 | 2021-10-13 | Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023000291A MX2023000291A (es) | 2019-04-17 | 2021-10-13 | Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel. |
Country Status (10)
Country | Link |
---|---|
US (2) | US11154533B2 (es) |
EP (2) | EP3955889A1 (es) |
JP (2) | JP7085073B2 (es) |
KR (2) | KR20220022115A (es) |
CN (1) | CN114206312A (es) |
AU (2) | AU2020258452B2 (es) |
CA (1) | CA3132958A1 (es) |
MX (2) | MX2021012548A (es) |
TW (1) | TW202106295A (es) |
WO (1) | WO2020214855A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
MX2021012548A (es) | 2019-04-17 | 2023-01-05 | Azora Therapeutics Inc | Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel. |
WO2022020332A1 (en) | 2020-07-21 | 2022-01-27 | Chembeau LLC | Diester cosmetic formulations and uses thereof |
CN117881649A (zh) * | 2021-07-02 | 2024-04-12 | 安基生技新药股份有限公司 | 二甲基姜黄素的外用调配物 |
CN117794893A (zh) * | 2021-08-06 | 2024-03-29 | 元启(苏州)生物制药有限公司 | 苯烯莫德的前药 |
CN113462770B (zh) * | 2021-08-25 | 2023-03-31 | 中国医科大学附属第一医院 | 趋化因子作为玫瑰痤疮诊断的分子标志物 |
WO2023159120A1 (en) * | 2022-02-16 | 2023-08-24 | Insmed Incorporated | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa |
WO2024050431A2 (en) * | 2022-08-30 | 2024-03-07 | Dermavant Sciences GmbH | Tapinarof and analogs thereof for use in treating ahr mediated diseases |
WO2024076731A1 (en) * | 2022-10-06 | 2024-04-11 | Regranion, Llc | Methods and compositions for treating hidradenitis suppurativa |
WO2024078468A1 (zh) * | 2022-10-10 | 2024-04-18 | 上海泽德曼医药科技有限公司 | 二苯乙烯衍生物用于预防和或治疗溃疡的用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981586A (en) * | 1997-05-23 | 1999-11-09 | Pershadsingh; Harrihar A. | Methods for treating proliferative and inflammatory skin diseases |
KR20110090892A (ko) * | 2008-10-31 | 2011-08-10 | 모베르그 데르마 아베 | 두 개 이상의 침투 증강제의 조합으로 구성되는 국소 조성물 |
CN107648216B (zh) | 2010-07-27 | 2021-03-30 | 波士顿大学管理委员会 | 作为新型癌症疗法的芳烃受体(AhR)调节剂 |
US10967031B2 (en) | 2010-12-28 | 2021-04-06 | Kamedis Ltd. | Synergistic herbal compositions with prebiotic properties for treatment of skin infections, allergies and inflammation |
TWI438000B (zh) * | 2011-02-18 | 2014-05-21 | Galderma Res & Dev | 青黛之經油萃取的產物及其製備方法與用途 |
US9821059B2 (en) * | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
CN104435505A (zh) * | 2015-01-09 | 2015-03-25 | 于成伟 | 一种治疗直肠炎的灌肠剂及其制备方法 |
TW201642890A (zh) * | 2015-04-09 | 2016-12-16 | 高德美公司 | 以青黛或產靛藍植物提取物治療異位性皮膚炎 |
WO2016162485A1 (en) * | 2015-04-09 | 2016-10-13 | Galderma Sa | A pharmaceutical composition and the use thereof |
US11122997B2 (en) | 2015-04-17 | 2021-09-21 | Mayo Foundation For Medical Education And Research | Modulating the aryl hydrocarbon receptor system to treat major depressive disorder |
EP3093016A1 (en) * | 2015-05-14 | 2016-11-16 | DIEFFETTI Cosmetici S.r.l. semplificata | Compositions for the treatment of psoriasis |
ES2914112T3 (es) * | 2015-05-21 | 2022-06-07 | Dermavant Sciences GmbH | Composiciones farmacéuticas tópicas |
MX2021012548A (es) | 2019-04-17 | 2023-01-05 | Azora Therapeutics Inc | Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel. |
-
2020
- 2020-04-16 MX MX2021012548A patent/MX2021012548A/es unknown
- 2020-04-16 WO PCT/US2020/028581 patent/WO2020214855A1/en active Search and Examination
- 2020-04-16 KR KR1020217037343A patent/KR20220022115A/ko not_active Application Discontinuation
- 2020-04-16 JP JP2021560597A patent/JP7085073B2/ja active Active
- 2020-04-16 EP EP20724649.7A patent/EP3955889A1/en not_active Withdrawn
- 2020-04-16 AU AU2020258452A patent/AU2020258452B2/en active Active
- 2020-04-16 CA CA3132958A patent/CA3132958A1/en active Pending
- 2020-04-16 CN CN202080036620.4A patent/CN114206312A/zh active Pending
- 2020-04-16 KR KR1020237023188A patent/KR20230110821A/ko active Application Filing
- 2020-04-16 EP EP23186707.8A patent/EP4252844A3/en active Pending
- 2020-04-17 TW TW109113027A patent/TW202106295A/zh unknown
-
2021
- 2021-03-05 US US17/194,146 patent/US11154533B2/en active Active
- 2021-10-01 US US17/492,377 patent/US20220023259A1/en active Pending
- 2021-10-13 MX MX2023000291A patent/MX2023000291A/es unknown
-
2022
- 2022-06-03 JP JP2022090863A patent/JP2022116295A/ja active Pending
- 2022-10-05 AU AU2022246403A patent/AU2022246403A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2023000291A (es) | 2023-02-09 |
US20210186931A1 (en) | 2021-06-24 |
EP3955889A1 (en) | 2022-02-23 |
CN114206312A (zh) | 2022-03-18 |
TW202106295A (zh) | 2021-02-16 |
US11154533B2 (en) | 2021-10-26 |
AU2020258452B2 (en) | 2022-10-20 |
KR20230110821A (ko) | 2023-07-25 |
CA3132958A1 (en) | 2020-10-22 |
WO2020214855A1 (en) | 2020-10-22 |
AU2022246403A1 (en) | 2022-11-03 |
JP7085073B2 (ja) | 2022-06-15 |
EP4252844A3 (en) | 2023-12-06 |
KR20220022115A (ko) | 2022-02-24 |
JP2022522540A (ja) | 2022-04-19 |
EP4252844A2 (en) | 2023-10-04 |
AU2020258452A1 (en) | 2021-11-04 |
JP2022116295A (ja) | 2022-08-09 |
US20220023259A1 (en) | 2022-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023000291A (es) | Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel. | |
CL2017002494A1 (es) | Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer | |
MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
BR112017013022A2 (pt) | métodos para tratar uma doença inflamatória e/ou autoimune aguda num mamífero que a necessite onde a terapia de corticosteróides é utilizada como terapia de primeira ou segunda linha e/ou para tratar uma doença inflamatória e/ou autoimune num mamífero que a necessite, onde a terapia de corticosteróides é utilizada como terapia de manutenção de primeira ou segunda linha e/ou para eliminar ou reduzir dose terapêutica de corticosteróides utilizado no tratamento de uma doença inflamatória e/ou autoimune num mamífero que a necessite, onde a terapia de corticosteróides é utilizada como terapia de manutenção crônica de primeira ou segunda linha e/ou de tratamento de uma doença autoimune e/ou inflamatória num mamífero que a necessite | |
CL2017000080A1 (es) | Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer | |
CO2021016768A2 (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos | |
CO2021016765A2 (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos | |
BR112018073920A2 (pt) | inibidores de pd-1/pd-l1 para tratamento de câncer". | |
BR112016014481A2 (pt) | tratamento de câncer utilizando combinações de inibidores de erk e raf | |
MX2015016277A (es) | Tratamiento de canceres utilizando moduladores de la isoforma pi3 cinasa. | |
MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
BR112018012255A2 (pt) | método para tratar câncer | |
BR112017007975A2 (pt) | composições e métodos para o tratamento de disfunção das glândulas meibomianas | |
CR20220325A (es) | Fluoroalquil-oxadiazoles y sus usos | |
EA201692334A1 (ru) | Кортикостероидные композиции для местного применения | |
FI20115135L (fi) | Mikrofibrilloitu selluloosa käytettäväksi erityisesti atooppisen ihotulehduksen ja psoriasiksen hoidossa | |
BR112016000335A8 (pt) | método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica | |
PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
MX2020004837A (es) | Inhibidores de la vía de adenosina para el tratamiento del cáncer. | |
CL2019001014A1 (es) | Métodos de tratamiento de afecciones relacionadas con la inflamación utilizando moduladores metabólicos y anti inflamatorios pluripotentes. | |
ZA201901367B (en) | Inhibition of olig2 activity | |
CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
CL2023001637A1 (es) | Inhibidores de la vía jak1 para el tratamiento del vitíligo. | |
BR112016030275A2 (pt) | Métodos para tratamento e redução dos sintomas da síndrome mão-pé (eritrodisestesia palmo-plantar) |